What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · BTI, GLN

Weight-loss drug users are stocking up on protein — buy nutrition and supplement stocks

The boom in weight-loss drugs is creating a massive new wave of customers buying protein powders and supplements. As people lose weight rapidly, they are stocking up on nutrition products to maintain muscle, sending nutrition company stocks higher.

Idea

Millions of people taking weight-loss drugs are shifting their diets to prioritize high protein intake to avoid losing muscle mass. This sudden lifestyle shift is translating into huge sales numbers for nutrition and supplement companies like Glanbia. As long as the prescription of these weight-loss drugs continues to trend up, the demand for protein powder should follow suit. Getting behind the secondary beneficiaries of the weight-loss drug craze offers a smart way to ride this consumer trend.

Key details

BTI GLND#consumer_staples#health#trend_following

Community

Upvotes

Views

Copies

Cosigns

News sources

GLP-1 Craze Fuels Protein-Powder Maker Glanbia’s Share Rally — Bloomberg

Related ideas

Fed rate-hike fears vanish as inflation cools — momentum play on Bitcoin